AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15787886 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 200 microg/day
Number of subjects: 2928
Study 15787886 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/day
Number of subjects: 2928
Study 15787886 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (high doses)
Number of subjects: 2928
Study 15787886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2928
Study 12456032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbent dialysis and standardized conventional medical treatment
Number of subjects: 20
Study 12456032 — intervention group
Group type: COMPARATOR
Intervention: Ongoing medical treatment alone
Number of subjects: 20
Study 10625865 — intervention group
Group type: EXPERIMENTAL
Intervention: PMS Symptom Management Program (PMS-SMP)
Number of subjects: 91
Study 10625865 — intervention group
Group type: COMPARATOR
Intervention: Waiting treatment group (control)
Number of subjects: 91
Study 8746608 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3 or 5 days)
Number of subjects: 131
Study 8746608 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (7 to 10 days)
Number of subjects: 131
Study 8746608 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 131
Study 8746608 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 131
Study 2207304 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lomefloxacin
Number of subjects: 30
Study 2207304 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg lomefloxacin
Number of subjects: 30
Study 2207304 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin
Number of subjects: 30
Study 2207304 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lomefloxacin
Number of subjects: 30
Study 2207304 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg lomefloxacin
Number of subjects: 30
Study 2207304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7445655 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (0.1 mg/kg i.v.)
Number of subjects: 40
Study 7445655 — intervention group
Group type: COMPARATOR
Intervention: D 600 (0.03 mg/kg i.v.)
Number of subjects: 40
Study 7445655 — intervention group
Group type: COMPARATOR
Intervention: Ro 11-1781 (1.0 mg/kg i.v.)
Number of subjects: 40
Study 30666700 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS203 (10 mg/kg body weight)
Number of subjects: 18
Study 30666700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28142347 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3 sessions
Number of subjects: 43
Study 28142347 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection - 80 mg methylprednisolone, 1 injection
Number of subjects: 43
Study 27565625 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation during pregnancy
Number of subjects: 492
Study 24210453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (970nm)
Number of subjects: 30
Study 24210453 — intervention group
Group type: COMPARATOR
Intervention: Surgical blade (control)
Number of subjects: 30
Study 21392096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 104
Study 21392096 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 104
Study 21392096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily) plus Simvastatin (40 mg daily)
Number of subjects: 104
Study 21392096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 19713268 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily movement training
Number of subjects: 26
Study 19713268 — intervention group
Group type: COMPARATOR
Intervention: Daily social training
Number of subjects: 26
Study 17539268 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-A: 300 mg DHA followed by 750 mg MQ and 300 mg DHA 6 and 24 hours later
Number of subjects: 12
Study 17539268 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-B: 300 mg DHA followed by 300 mg DHA and 750 mg MQ at 24 hours
Number of subjects: 12
Study 15126524 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor (LAF237); 100 mg daily, n = 18
Number of subjects: 37
Study 15126524 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 19
Number of subjects: 37
Study 11274902 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus sulodexide (IS)
Number of subjects: 18
Study 11274902 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus placebo (IP)
Number of subjects: 18
Study 9607373 — intervention group
Group type: COMPARATOR
Intervention: 50 mg mibefradil
Number of subjects: 0
Study 9607373 — intervention group
Group type: COMPARATOR
Intervention: 100 mg mibefradil
Number of subjects: 0
Study 7521713 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) 1500 mg
Number of subjects: 26
Study 7521713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7521713 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 26
Study 2683326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (400 mg tablet once daily)
Number of subjects: 106
Study 2683326 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (160 mg)/sulfamethoxazole (800 mg, one tablet every 12 hours)
Number of subjects: 106
Study 821573 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy during surgical treatment
Number of subjects: 0
Study 821573 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy during surgical treatment
Number of subjects: 0
Study 30345864 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil citrate 20 mg orally three times a day, in addition to fish oil and zinc supplementation
Number of subjects: 46
Study 30345864 — intervention group
Group type: COMPARATOR
Intervention: placebo (tablets similar to sildenafil)
Number of subjects: 46
Study 30596830 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to conflicting information about mammography (no, low, medium, or high conflict)
Number of subjects: 1474
Study 30596830 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of exposure to conflicting information
Number of subjects: 1474
Study 30596830 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic position
Number of subjects: 1474
Study 27484290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 0
Study 26252751 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD with CHX
Number of subjects: 85
Study 26252751 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD with AZ
Number of subjects: 85
Study 26252751 — intervention group
Group type: EXPERIMENTAL
Intervention: QS with CHX
Number of subjects: 85
Study 26252751 — intervention group
Group type: EXPERIMENTAL
Intervention: QS with AZ
Number of subjects: 85
Study 26252751 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD without adjuvants
Number of subjects: 85
Study 26252751 — intervention group
Group type: EXPERIMENTAL
Intervention: QS without adjuvants
Number of subjects: 85
Study 23447432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 38
Study 23447432 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 38
Study 20886231 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 58
Study 20886231 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 58
Study 18183403 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,350 ml of low-density barium (VoLumen)
Number of subjects: 80
Study 18183403 — intervention group
Group type: COMPARATOR
Intervention: 900 ml of low-density barium (VoLumen) and 450 ml of water
Number of subjects: 80
Study 17058279 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis in Calgary (Post)
Number of subjects: 2033
Study 17058279 — intervention group
Group type: COMPARATOR
Intervention: No palivizumab prophylaxis in Edmonton (Control)
Number of subjects: 2033
Study 17058279 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis in Calgary for moderate-risk infants
Number of subjects: 2033
Study 15575828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 138
Study 15575828 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 138
Study 11106051 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (preterm infants with apnoeas)
Number of subjects: 36
Study 11106051 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 36
Study 9088654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cow milk challenge (DBPCFC)
Number of subjects: 83
Study 1545355 — intervention group
Group type: EXPERIMENTAL
Intervention: 155-mg oral tablet of hydroxychloroquine
Number of subjects: 9
Study 1545355 — intervention group
Group type: COMPARATOR
Intervention: 155-mg iv infusion of racemic hydroxychloroquine
Number of subjects: 9
Study 1545355 — intervention group
Group type: EXPERIMENTAL
Intervention: Deconvolution methods (staircase, delta function, least squares)
Number of subjects: 9
Study 3903646 — intervention group
Group type: EXPERIMENTAL
Intervention: NIAID vaccine
Number of subjects: 180
Study 3903646 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVS vaccine
Number of subjects: 180
Study 3903646 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine + hepatitis B immune globulin
Number of subjects: 180
Study 3903646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 30607062 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional commitment assessment
Number of subjects: 442
Study 30607062 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived maternal health goal scale assessment
Number of subjects: 442
Study 30607062 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with professional commitment
Number of subjects: 442
Study 28276210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour group education program with parents
Number of subjects: 0
Study 28276210 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25362672 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid blood withdrawal (5 seconds)
Number of subjects: 50
Study 25362672 — intervention group
Group type: COMPARATOR
Intervention: Slow blood withdrawal (1 to 2 minutes)
Number of subjects: 50
Study 22545593 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester braided thread (Mersilene™ or Ethibond™)
Number of subjects: 138
Study 22545593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilene tape™
Number of subjects: 138
Study 20717750 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal hemoglobin (HGB) concentration of at least 11.5 g/dl
Number of subjects: 44
Study 20717750 — intervention group
Group type: COMPARATOR
Intervention: Goal hemoglobin (HGB) concentration of at least 10 g/dl
Number of subjects: 44
Study 18311494 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP alone
Number of subjects: 18
Study 18311494 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP and NML
Number of subjects: 18
Study 18311494 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP and HH
Number of subjects: 18
Study 16086946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of travoprost 0.004%/timolol 0.5% once daily
Number of subjects: 403
Study 16086946 — intervention group
Group type: COMPARATOR
Intervention: Concomitant travoprost 0.004% every evening + timolol 0.5% every morning
Number of subjects: 403
Study 16086946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of travoprost 0.004%/timolol 0.5%
Number of subjects: 403
Study 16086946 — intervention group
Group type: COMPARATOR
Intervention: Concomitant travoprost + timolol
Number of subjects: 403
Study 12451188 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 44 micro g subcutaneously three times weekly (tiw)
Number of subjects: 677
Study 12451188 — intervention group
Group type: COMPARATOR
Intervention: IFNbeta‐1a 30 micro g IM once weekly (qw)
Number of subjects: 677
Study 12451188 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 44 micro g tiw
Number of subjects: 677
Study 12451188 — intervention group
Group type: COMPARATOR
Intervention: IFNbeta‐1a 30 micro g qw
Number of subjects: 677
Study 11044464 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS treatment for 6 months
Number of subjects: 67
Study 11044464 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS treatment for 12 months
Number of subjects: 67
Study 8960647 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 meals per day (2M group)
Number of subjects: 12
Study 8960647 — intervention group
Group type: COMPARATOR
Intervention: 6 meals per day (6M group)
Number of subjects: 12
Study 1332987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxylapatite particles implantation
Number of subjects: 10
Study 1332987 — intervention group
Group type: COMPARATOR
Intervention: Control (no implant)
Number of subjects: 10
Study 4015741 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg/ml intravenous injection or infusion
Number of subjects: 12
Study 4015741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30066171 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal approach
Number of subjects: 0
Study 30066171 — intervention group
Group type: COMPARATOR
Intervention: Intercostal approach
Number of subjects: 0
Study 28735835 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled second-look endoscopy (EGD) 24 to 36 hours after initial hemostasis
Number of subjects: 319
Study 28735835 — intervention group
Group type: COMPARATOR
Intervention: Initial endoscopic hemostasis without scheduled second-look EGD
Number of subjects: 319
Study 28735835 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled second-look endoscopy (EGD)
Number of subjects: 319
Study 26439431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow non-hematopoietic stem cells (NHBMSC) with cyclosporine
Number of subjects: 14
Study 26439431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow non-hematopoietic stem cells (NHBMSC) without cyclosporine
Number of subjects: 14
Study 26439431 — intervention group
Group type: COMPARATOR
Intervention: Both groups (NHBMSC with and without cyclosporine)
Number of subjects: 14
Study 24423366 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 70 μg (2800 IU) cholecalciferol for 52 weeks
Number of subjects: 46
Study 24423366 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo for 52 weeks
Number of subjects: 46
Study 22885606 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphones
Number of subjects: 28
Study 22885606 — intervention group
Group type: COMPARATOR
Intervention: No headphones (Control)
Number of subjects: 28
Study 20417427 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical resection of the polyp
Number of subjects: 150
Study 20417427 — intervention group
Group type: COMPARATOR
Intervention: Observation for 6 months
Number of subjects: 150
Study 18414870 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral oral contrast agent (3% mannitol)
Number of subjects: 100
Study 18414870 — intervention group
Group type: COMPARATOR
Intervention: Positive oral contrast medium
Number of subjects: 100
Study 15781099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil
Number of subjects: 497
Study 15781099 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor
Number of subjects: 497
Study 15781099 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 497
Study 14623527 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 14623527 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0
Study 14623527 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study 10559527 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 11
Study 10559527 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 11
Study 10559527 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirits
Number of subjects: 11
Study 10559527 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study 8880676 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (5 or more treatments)
Number of subjects: 77
Study 8880676 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 or fewer treatments or refused)
Number of subjects: 77
Study 29656600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SFOH) 1.0-3.0 g/day
Number of subjects: 100
Study 29656600 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer 2.4-14.4 g/day
Number of subjects: 100
Study 27151071 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality cognitive therapy
Number of subjects: 30
Study 27151071 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality exposure
Number of subjects: 30
Study 23772990 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 1582
Study 23772990 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous
Number of subjects: 1582
Study 23301470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint autohemotherapy
Number of subjects: 45
Study 23301470 — intervention group
Group type: COMPARATOR
Intervention: Loratadine tablets (western medication)
Number of subjects: 45
Study 20845511 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR‐ILBT group (n = 17)
Number of subjects: 36
Study 20845511 — intervention group
Group type: COMPARATOR
Intervention: EBRT group (n = 19)
Number of subjects: 36
Study 17697063 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (once-daily)
Number of subjects: 819
Study 16274417 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (1.5 mg/kg per day)
Number of subjects: 6
Study 16274417 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (3.0 mg/kg per day)
Number of subjects: 6
Study 16274417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12165681 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 0.09 IU.kg BW(‐1).d(‐1) for 6 days a week (A trial)
Number of subjects: 7
Study 12165681 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 0.09 IU.kg BW(‐1).d(‐1) for 3 days a week (B trial)
Number of subjects: 7
Study 10219654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and famotidine (H1- and H2-receptor antagonist)
Number of subjects: 80
Study 10219654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (H1-receptor antagonist)
Number of subjects: 80
Study 10219654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 80
Study 7529522 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP (mitomycin 6 mg m‐2, ifosfamide 3 g m‐2, cisplatinum 80 mg m‐2 on day 1 every 28 days)
Number of subjects: 93
Study 7529522 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP-IFN (MIP and interferon alpha‐2b 3 MU s.c. three times a week)
Number of subjects: 93
Study 7529522 — intervention group
Group type: COMPARATOR
Intervention: PC (cisplatinum 60 mg m‐2 and carboplatin 400 mg m‐2 on day 1 every 28 days)
Number of subjects: 93
Study 7529522 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 93
Study 2212185 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term dynamically oriented individual therapy
Number of subjects: 144
Study 2212185 — intervention group
Group type: COMPARATOR
Intervention: low QOR control group
Number of subjects: 144
Study 727423 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate (10 ml 10%)
Number of subjects: 44
Study 727423 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (10 ml 5.5%)
Number of subjects: 44
Study 31366332 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforation with application of autologous blood
Number of subjects: 165
Study 31366332 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforation with application of dextrose
Number of subjects: 165
Study 31366332 — intervention group
Group type: COMPARATOR
Intervention: Perforation only
Number of subjects: 165
Study 27890156 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase change cooling (PCC) garment
Number of subjects: 20
Study 27890156 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 26525549 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood combined with hydroxychloroquine sulfate tablets
Number of subjects: 70
Study 26525549 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate tablets alone
Number of subjects: 70
Study 24225205 — intervention group
Group type: EXPERIMENTAL
Intervention: Home medication review (HMR) and medication management (MM) conducted by Dementia Care Manager (DCM) in cooperation with pharmacists and general practitioners.
Number of subjects: 0
Study 24225205 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and provision of regularly updated information to pharmacists involved in the MM.
Number of subjects: 0
Study 19575742 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified patient-maintained target-controlled infusion (TCI) of propofol
Number of subjects: 100
Study 19575742 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled Entonox inhalation
Number of subjects: 100
Study 20614697 — intervention group
Group type: EXPERIMENTAL
Intervention: Better control (Hb A1c < 9%)
Number of subjects: 126
Study 20614697 — intervention group
Group type: COMPARATOR
Intervention: Poor control (Hb A1c > 9%)
Number of subjects: 126
Study 16765849 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music with movement intervention (twice a week for 4 weeks)
Number of subjects: 36
Study 16765849 — intervention group
Group type: COMPARATOR
Intervention: Usual care without intervention
Number of subjects: 36
Study 15301650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in group therapy format
Number of subjects: 45